Article
Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
Antiviral therapy - 1 Jan 2020
Ren Shan, Wei Feili, Jin Yi, Lu Junfeng, He Zhimin, Ma Lina, Zheng Yanhong, Wang Junli, Chen Xinyue
Abstract excerpt
BACKGROUND: To evaluate the impact of baseline resistance-associated substitutions (RASs) on direct-acting antiviral (DAA) treatment response among pegylated interferon in combination with ribavirin (PR) failing patients in a real-life setting. METHODS: Blood samples and clinical data from 171 patients who failed PR treatment were collected. All of them received rescue DAA regimens. RAS identified in the NS3,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.